Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference
Prime Medicine, a biotechnology company specializing in one-time curative genetic therapies, has announced that its President and CEO, Keith Gottesdiener, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA.
A live audio webcast of the presentation will be accessible under the “Events & Presentations” section on the company’s website, www.primemedicine.com. Additionally, a replay of the webcast will be available on the website for 30 days after the presentation.
Prime Medicine, una società biotecnologica specializzata in terapie genetiche curative una tantum, ha annunciato che il suo Presidente e CEO, Keith Gottesdiener, M.D., parteciperà al 43° Congresso Annuale J.P. Morgan Healthcare. La presentazione è programmata per martedì 14 gennaio 2025, alle 15:00 PT (18:00 ET) a San Francisco, CA.
Un webcast audio in diretta della presentazione sarà accessibile nella sezione “Eventi & Presentazioni” sul sito web dell'azienda, www.primemedicine.com. Inoltre, un ripasso del webcast sarà disponibile sul sito per 30 giorni dopo la presentazione.
Prime Medicine, una empresa de biotecnología especializada en terapias genéticas curativas de una sola dosis, ha anunciado que su Presidente y CEO, Keith Gottesdiener, M.D., presentará en la 43ª Conferencia Anual de Salud J.P. Morgan. La presentación está programada para el martes 14 de enero de 2025, a las 3:00 p.m. PT (6:00 p.m. ET) en San Francisco, CA.
Un webcast de audio en vivo de la presentación estará disponible en la sección “Eventos y Presentaciones” en el sitio web de la compañía, www.primemedicine.com. Además, una repetición del webcast estará disponible en el sitio durante 30 días después de la presentación.
프라임 메디신, 일회성 치료 유전자 요법에 전문화된 생명공학 회사가 키스 고테스디너 사장 겸 CEO가 제43회 JP모건 헬스케어 컨퍼런스에서 발표할 것이라고 발표했습니다. 발표는 2025년 1월 14일 화요일 오후 3시 PT (오후 6시 ET)에 샌프란시스코, CA에서 예정되어 있습니다.
발표의 실시간 오디오 웹캐스트는 회사 웹사이트의 “이벤트 및 프레젠테이션” 섹션에서 접근할 수 있으며, www.primemedicine.com에서 확인할 수 있습니다. 또한 웹캐스트 재방송은 발표 이후 30일 동안 웹사이트에서 제공될 예정입니다.
Prime Medicine, une entreprise de biotechnologie spécialisée dans les thérapies géniques curatives uniques, a annoncé que son Président et CEO, Keith Gottesdiener, M.D., fera une présentation lors de la 43e Conférence Annuelle J.P. Morgan Healthcare. La présentation est prévue pour le mardi 14 janvier 2025, à 15h00 PT (18h00 ET) à San Francisco, CA.
Un webinaire audio en direct de la présentation sera accessible dans la section « Événements & Présentations » sur le site web de l'entreprise, www.primemedicine.com. De plus, une rediffusion du webinaire sera disponible sur le site pendant 30 jours après la présentation.
Prime Medicine, ein Biotechnologieunternehmen, das sich auf einmalige kurative Gentherapien spezialisiert hat, hat bekannt gegeben, dass sein Präsident und CEO, Keith Gottesdiener, M.D., auf der 43. jährlichen J.P. Morgan Healthcare-Konferenz präsentieren wird. Die Präsentation ist für Dienstag, den 14. Januar 2025, um 15:00 Uhr PT (18:00 Uhr ET) in San Francisco, CA, angesetzt.
Ein live Audio-Webcast der Präsentation wird im Bereich „Veranstaltungen & Präsentationen“ auf der Website des Unternehmens unter www.primemedicine.com zugänglich sein. Zusätzlich wird eine Wiederholung des Webcasts auf der Website für 30 Tage nach der Präsentation verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA.
A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 30 days following the presentation.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology and oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
© 2025 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Investor Contact
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com
FAQ
When will Prime Medicine present at the J.P. Morgan Healthcare Conference?
Who is presenting for Prime Medicine at the J.P. Morgan Healthcare Conference?
Where can I watch Prime Medicine's presentation at the J.P. Morgan Healthcare Conference?
How long will the replay of Prime Medicine’s presentation be available?
What is the stock symbol for Prime Medicine?
What type of therapies does Prime Medicine specialize in?
Where is Prime Medicine presenting its corporate overview?
What time is Prime Medicine's presentation in Eastern Time?
